Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re

International Immunopharmacology

Volumn 10, Issue 3, 2010, Pages 351-356

  Song, Xiaoming ^a,c   Chen, Jian ^a   Sakwiwatkul, Kedsirin ^a   Li, Ruili ^a   Hu, Songhua ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Ginsenoside; Influenza; Re; Th1 Th2

Indexed keywords

GAMMA INTERFERON; GINSENOSIDE RE; HEMAGGLUTININ; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INFLUENZA VACCINE; INTERLEUKIN 5; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG ISOLATION; FEMALE; GINSENG; HEMAGGLUTINATION TEST; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS A H3N2; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL; VIRUS INACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL PROLIFERATION; FEMALE; GINSENOSIDES; HEMAGGLUTINATION INHIBITION TESTS; IMMUNIZATION; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-5; LYMPHOCYTES; MICE; MICE, INBRED ICR; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 76849115746     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.12.009     Document Type: Article

References (43)

1. Wright P.F., Neuman G., and Kawaoka Y. Orthomyxoviruses. In: Knipe D.M., Howley P.M., Griffin D.E., Martin M.A., Ramb R.A., Roizman B., et al. (Eds). Fields virology 5th ed (2007), Philadelphia Lippincott-Raven 1691-1740
2. McCullers J.A., and Rehg J.E. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186 3 (2002) 341-350
3. Okamoto S., Kawabata S., Nakagawa I., Okuno Y., Goto T., Sano K., et al. Influenza A virus-infected hosts boost an invasive type of Streptococcus pyogenes infection in mice. J Virol 77 7 (2003) 4104-4112
4. Sweet C., and Smith H. Pathogenicity of influenza virus. Microbiol Rev 44 2 (1980) 303-330
5. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 9101 (1998) 472-477
6. de Jong M.D., Bach V.C., Phan T.Q., Vo M.H., Tran T.T., Nguyen B.H., et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352 7 (2005) 686-691
7. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79 18 (2005) 11788-11800
8. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 5349 (1998) 393-396
9. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., and Pham P.M. Nguyen vVC, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 12 (2004) 1179-1188
10. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 4 (2005) 333-340
11. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 16 (2003) 1769-1775
12. Nichol K.L., Wuorenma J., and von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158 16 (1998) 1769-1776
13. Okamoto S., Kawabata S., Fujitaka H., Uehira T., Okuno Y., and Hamada S. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. Vaccine 22 21-22 (2004) 2887-2893
14. Vu T., Farish S., Jenkins M., and Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20 13-14 (2002) 1831-1836
15. Maeda T., Shintani Y., Nakano K., Terashima K., and Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months. Pediatr Int 46 2 (2004) 122-125
16. Diseases AAoPCoI. Recommendations for influenza immunization of children. Pediatrics 113 (2004) 1441-1447
17. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 2 (2000) 168-175
18. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., and Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61 1 (2000) 94-99
19. Gupta R.K., Rost B.E., Relyveld E., and Siber G.R. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol 6 (1995) 229-248
20. Aguilar J.C., and Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 25 19 (2007) 3752-3762
21. CP L.I., and Li R.C. An introductory note to ginseng. Am J Chin Med 1 2 (1973) 249-261
22. Owen R.T. Ginseng: a pharmacological profile. Drugs Today 8 (1981) 343-351
23. Rivera E., Hu S., and Concha C. Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants. Vaccine 21 11-12 (2003 Mar 7) 1149-1157
24. Hu S., Concha C., and Lin F. Persson Waller K. Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immunol Immunopathol 91 1 (2003 Jan 10) 29-37
25. Rivera E., Daggfeldt A., and Hu S. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol 91 1 (2003 Jan 10) 19-27
26. Rivera E. Ekholm Pettersson F, Inganas M, Paulie S, Gronvik KO. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine 23 46-47 (2005 Nov 16) 5411-5419
27. Song X., Bao S., Wu L., and Hu S. Ginseng stem-leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice. Vaccine 27 1 (2009 Jan 1) 51-55
28. Liu C.X., and Xiao P.G. Recent advances on ginseng research in China. J Ethnopharmacol 36 1 (1992) 27-38
29. Sun J., Hu S., and Song X. Adjuvant effects of protopanaxadiol and protopanaxatriol saponins from ginseng roots on the immune responses to ovalbumin in mice. Vaccine 25 6 (2007 Jan 22) 1114-1120
30. Wang T.S. Extraction and isolation of ginsenosides from stems and leaves of Panax ginseng. In: Wang T.S. (Ed). China ginseng (2001), Liaoning Science and Technology Publishing House, China, Shenyang 692-693
31. In: Kendal A.P., Skehel J.J., and Pereira M. (Eds). World Health Organization Collaborating Centers for reference and research on influenza concepts and procedures for laboratory-based influenza surveillance (1982), Centers for Disease Control and Prevention, Atlanta B17-B35
32. Prabakaran M., Velumani S., He F., Karuppannan A.K., Geng G.Y., Yin L.K., et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380 2 (2008) 412-420
33. Cox R.J., Hovden A.-O., Brokstad K.A., Szyszko E., Madhun A.S., and Haaheim L.R. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine 24 44-46 (2006) 6585-6587
34. Constant S.L., and Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15 (1997) 297-322
35. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160 2 (1998) 870-876
36. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162 7 (1999) 3942-3949
37. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15 4 (2003) 505-514
38. Mazumdar T., Anam K., and Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22 9-10 (2004) 1162-1171
39. Okamoto S., Yoshii H., Akagi T., Akashi M., Ishikawa T., Okuno Y., et al. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25 49 (2007) 8270-8278
40. Gelder C.M., Lamb J.R., and Askonas B.A. Human CD4+ T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J Virol 70 7 (1996) 4787-4790
41. McMichael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol 189 (1994) 75-91
42. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., and Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26 19 (2008) 2350-2359
43. Tizard IR. Veterinary immunology: an introduction. 6th ed (2000), Saunders WB, Co, Philadelphia 1-8